Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01884363 · ClinicalTrials.gov registry record · NA

Walnut Consumption, Endothelial Function, and Biomarkers

A NA study of Type 2 Diabetes and Coronary Heart Disease, sponsored by Brigham and Women's Hospital.

Completed
Registry status
NA
Development phase
26
Enrollment target
1
Study location

NCT01884363: Completed NA study of Type 2 Diabetes and Coronary Heart Disease, sponsored by Brigham and Women's Hospital.

NCT01884363 is a NA study of Type 2 Diabetes and Coronary Heart Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 26 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01884363, a NA study of Type 2 Diabetes and Coronary Heart Disease, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

This study will examine whether a twelve-week intervention with one ounce (28 g) per day of walnuts improves endothelial function measured non-invasively using finger probe (EndoPat-2000) in people with coronary heart disease or type 2 diabetes.

Primary Outcome

Reactive hyperemia index (RHI), which in part reflects vasodilator function of the small blood vessel at the fingertips is an indirect measure of endothelial function. Change in RHI between baseline and 12 weeks post intervention will be measured in each group using EndoPat2000 device. We will compare RHI change between walnut group and usual diet group.

Interventions

  • OTHER Once ounce per day of walnuts

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2013-06
Est. Completion 2015-09
Phase NA
Brigham and Women's Hospital

937 total trials

What the finished NCT01884363 record still lists

NCT01884363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Once ounce per day of walnuts is the first listed.

NCT01884363 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01884363 about?

NCT01884363 is a clinical study titled "Walnut Consumption, Endothelial Function, and Biomarkers". This study will examine whether a twelve-week intervention with one ounce (28 g) per day of walnuts improves endothelial function measured non-invasively using finger probe (EndoPat-2000) in people with coronary heart disease or type 2 diabetes.

What is the current status of trial NCT01884363?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2013-06. Estimated completion is 2015-09.

What conditions does trial NCT01884363 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Coronary Heart Disease.

What interventions are being tested in trial NCT01884363?

The interventions under investigation include: Once ounce per day of walnuts (OTHER).

Who is sponsoring clinical trial NCT01884363?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01884363 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01884363's enrollment target sits among peer trials

26 273rd of 327 higher than 53 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01884363, the US trial registry maintained by the National Library of Medicine. NCT01884363 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.